The current biological issues driving the evolutionary progression of coronary artery disease are in focus: at this stage, the biological evidence for them is scarce and small in scale, with the exception of metabolomics and microbiomics. Issues such as histologic mapping of coronary atherosclerosis deterioration remain to be corroborated by more clinical and basic evidence! By analyzing the clinical data and multi-omics data of patients with coronary heart disease, investigators will explore the related risk factors and establish molecular subtypes and prognostic prediction models for individualized prediction of coronary heart disease risk, in order to guide the clinical screening of high-risk groups of coronary heart disease and formulate more targeted intervention countermeasures.
aged more than 18 years
meet the diagnostic criteria of coronary heart disease
undergo coronary angiography after admission and have at least 50% stenosis in at least one major coronary artery
able to sign the informed consent form
severe valvular disease (defined as valvular disease stage C or D)
hypertrophic cardiomyopathy; pulmonary heart disease 2) gastrointestinal disease
hyperthyroidism, anemia, or any other high-intensity heart disease
malignant tumors
The investigators aim to collect a population of patients with atherosclerotic heart disease who met inclusion exclusion criteria for four clinical phenotypes/groups (AMI, US, CCS, NCA).
Cohort
Prospective
Not listed
ACM
All-cause mortality
MACE
Major cardiovascular events
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
